CStone's Triple-Action Cancer Drug Shows Transformative Results

SUZHOU, China – March 26, 2026 – CStone Pharmaceuticals has unveiled striking early-stage clinical data for its novel trispecific antibody, CS2009, demonstrating what could be a paradigm shift in cancer treatment. The drug achieved an unprecedented 90% overall response rate (ORR) when used as a monotherapy in a cohort of first-line non-small cell lung cancer (NSCLC) patients, a result that significantly surpasses current standards of care.

Announced today, the updated Phase I/II trial results also highlight the drug's potent efficacy in notoriously difficult-to-treat malignancies, often called "cold tumors," alongside a favorable safety profile that avoids the severe toxicities of some combination immunotherapies. With plans to launch global Phase III trials by the end of the year, CStone is positioning CS2009 as a potential first- or best-in-class therapy poised to challenge treatment conventions across a wide spectrum of solid tumors.

A New Benchmark in Lung Cancer Efficacy

The most compelling data from the ongoing trials comes from a cohort of ten first-line NSCLC patients whose tumors showed high levels of PD-L1 (TPS ≥ 50%). In this group, treatment with CS2009 as a single agent resulted in tumors shrinking in nine out of ten patients, yielding a 90% ORR. Furthermore, every patient in the cohort experienced clinical benefit, achieving a 100% disease control rate (DCR).

To put this in perspective, the current standard of care for this patient population, pembrolizumab (Keytruda) monotherapy, established an ORR of approximately 45% in its pivotal KEYNOTE-024 trial. While direct cross-trial comparisons must be made with caution due to differences in size and design, CS2009's early results suggest a profound leap in efficacy.

"Based on the latest clinical data for CS2009, we are confident in its potential to transform treatment paradigms across a broad spectrum of tumor types," said Dr. Jason Yang, CEO and President of R&D at CStone, in a statement. He credited the results to the drug's unique molecular design and differentiated mechanism. The company also noted promising activity when CS2009 was combined with standard chemotherapy in first-line NSCLC and colorectal cancer (CRC), where it was well-tolerated and showed high objective response rates.

Cracking the Code of 'Cold Tumors'

Beyond its success in lung cancer, CS2009 is demonstrating remarkable potential in cancers that have historically been resistant to immunotherapy. These "cold tumors" lack the pre-existing immune cell infiltration that checkpoint inhibitors like PD-1 blockers rely on to be effective, leaving patients with few good options.

CS2009 appears to overcome this barrier. In heavily pretreated patients with non-clear cell renal cell carcinoma (nccRCC), a notoriously challenging kidney cancer subtype, the drug achieved a 40% ORR. In another cohort of patients with advanced soft tissue sarcoma (STS), a diverse and difficult group of cancers, CS2009 monotherapy produced a 33.3% ORR. These response rates are significantly higher than those typically seen with standard chemotherapies or single-agent immunotherapies in these settings, which often hover in the 10-20% range.

The drug's power lies in its innovative trispecific design. As a single molecule, it simultaneously targets three clinically validated pathways crucial for tumor growth and immune evasion: PD-1, CTLA-4, and VEGFA. By blocking the PD-1 and CTLA-4 immune checkpoints, it unleashes the body's T cells to attack cancer. Concurrently, by inhibiting VEGFA, it chokes off the tumor's blood supply and helps remodel the tumor microenvironment, making it more hospitable for the newly activated T cells. This synergistic, three-pronged attack appears capable of turning immunologically "cold" tumors "hot."

The Critical Safety Advantage

Combining PD-1 and CTLA-4 inhibitors has long been a strategy to boost anti-tumor immunity, but it often comes at the cost of severe, sometimes life-threatening, immune-related side effects. CStone's data suggests CS2009 may deliver the power of this combination without the associated toxicity.

Across 113 patients in the Phase I portion of the trial with a median follow-up of six months, the rate of severe (Grade ≥3) treatment-related adverse events (TRAEs) was a manageable 23%. Critically, the company reported "no excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed." Furthermore, severe side effects related to the VEGF inhibition were low, at just 4.4%.

This favorable safety profile, if it holds up in larger trials, could be a major competitive advantage. Offering the efficacy of a powerful multi-drug regimen in a single, better-tolerated infusion would simplify treatment and significantly improve the quality of life for patients undergoing aggressive cancer therapy.

A Global Ambition Fueled by Innovation

With these encouraging results in hand, CStone is moving forward with an ambitious global development strategy. The company plans to initiate the first wave of multi-regional Phase III clinical trials by the end of 2026, targeting major indications including NSCLC, colorectal cancer, and small cell lung cancer (SCLC). The U.S. FDA has already approved its application to begin Phase II studies in the country, complementing ongoing trials in China and Australia.

This global push reflects CStone's evolution into a significant player in the international biopharma landscape. Founded in 2015, the company has successfully brought four innovative drugs to market and has a history of forging major partnerships, including a landmark collaboration with Pfizer for its PD-L1 inhibitor sugemalimab. Dr. Yang confirmed that CStone is already in "advanced partnership discussions with several global multinational pharmaceutical companies" for CS2009, signaling strong external interest in the asset.

The oncology community will be eagerly awaiting a more detailed look at the data, which CStone plans to present at either the American Society of Clinical Oncology (ASCO) Annual Meeting or the European Society for Medical Oncology (ESMO) Congress later this year. These presentations will be critical for peer review and will further clarify whether CS2009's early promise will translate into a new pillar of cancer care for patients worldwide.